Terug
Ook genoteerd als
SBMFF
OTC
Dagbereik
€ 15,89
€ 17,65
52-Weeksbereik
€ 8,76
€ 20,16
Volume
100
50D / 200D Gem.
€ 16,44
/
€ 17,55
Vorige Slotkoers
€ 15,89
Koershistorie
Financiële Trends
Sectorvergelijking
vs Healthcare sector mediaan (626 peers)
| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | 4,1 | 0,4 |
| P/B | 0,4 | 2,9 |
| ROE % | 11,2 | 3,8 |
| Net Margin % | 12,1 | 3,9 |
| Rev Growth 5Y % | 5,1 | 10,0 |
| D/E | 0,3 | 0,2 |
Koersdoel Analisten
Geen analistendekking beschikbaar
Winstschattingen
| Periode | WPA Sch. | Omzet Sch. | Analisten |
|---|---|---|---|
| FY2026 |
€ 0,00
€ 0,00 – € 0,00
|
250 B | 0 |
Belangrijkste Punten
Revenue grew 5,11% annually over 5 years — modest growth
Earnings grew 50,08% over the past year
ROE of 11,21% — decent returns on equity
Debt/Equity of 0,31 — conservative balance sheet
Generating 5,22B in free cash flow
P/E of 4,06 — trading at a low valuation
Groei
Revenue Growth (5Y)
5,11%
Revenue (1Y)10,18%
Earnings (1Y)50,08%
FCF Growth (3Y)7,01%
Kwaliteit
Return on Equity
11,21%
ROIC11,02%
Net Margin12,12%
Op. Margin21,26%
Veiligheid
Debt / Equity
0,31
Current Ratio1,26
Interest Coverage20,79
Waardering
P/E Ratio
4,06
P/B Ratio0,44
EV/EBITDA2,35
Dividend Yield0,04%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 10,18% | Revenue Growth (3Y) | 5,31% |
| Earnings Growth (1Y) | 50,08% | Earnings Growth (3Y) | 17,30% |
| Revenue Growth (5Y) | 5,11% | Earnings Growth (5Y) | 6,01% |
| Profitability | |||
| Revenue (TTM) | 28,87B | Net Income (TTM) | 3,50B |
| ROE | 11,21% | ROA | 5,35% |
| Gross Margin | 81,51% | Operating Margin | 21,26% |
| Net Margin | 12,12% | Free Cash Flow (TTM) | 5,22B |
| ROIC | 11,02% | FCF Growth (3Y) | 7,01% |
| Safety | |||
| Debt / Equity | 0,31 | Current Ratio | 1,26 |
| Interest Coverage | 20,79 | Dividend Yield | 0,04% |
| Valuation | |||
| P/E Ratio | 4,06 | P/B Ratio | 0,44 |
| P/S Ratio | 0,49 | PEG Ratio | 0,10 |
| EV/EBITDA | 2,35 | Dividend Yield | 0,04% |
| Market Cap | 14,21B | Enterprise Value | 14,42B |
Income Statement
Annual, most recent first
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | 28,87B | 26,20B | 26,03B | 26,86B | 23,65B |
| Net Income | 3,50B | 2,33B | 2,54B | 14,61B | 2,77B |
| EPS (Diluted) | 3,80 | 1,99 | 2,40 | 14,60 | 3,00 |
| Gross Profit | 23,53B | 21,21B | 21,54B | 21,53B | 18,46B |
| Operating Income | 6,14B | 5,79B | 5,59B | 5,08B | 4,19B |
Balance Sheet
Annual, most recent first
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Total Assets | 65,41B | 63,60B | 64,06B | 60,54B | 47,21B |
| Total Liabilities | 22,63B | 25,43B | 26,12B | 22,81B | 24,79B |
| Shareholders' Equity | 31,96B | 30,47B | 29,75B | 30,29B | 16,75B |
| Total Debt | 9,78B | 12,58B | 13,98B | 12,12B | 14,21B |
| Cash & Equivalents | 9,57B | 9,45B | 8,65B | 9,60B | 10,62B |
| Current Assets | 24,69B | 23,81B | 25,93B | 23,50B | 22,79B |
| Current Liabilities | 19,56B | 22,61B | 20,15B | 15,35B | 10,94B |
Strategiescores
This stock passed the criteria for 3 strategies
Score = fit strength (0–100)
Rank = position among all matches
Recente Activiteit
Ingestapt
Cash Flow Compounder
Mar 24, 2026
Ingestapt
Deep Value Investing (Seth Klarman)
Mar 24, 2026
Ingestapt
Defensive Investing (Benjamin Graham)
Mar 24, 2026